Identification of end phenotypes in the behavioral-variant of front temporal dementia the purpose of this proposal is to develop the expertise necessary to establish an independent lab investigating end phenotypes in young-onset neurodegenerative conditions. The behavioral-variant of fronto temporal dementia (bvFTD) is the most common clinical phenotype in front temporal lobar degeneration (FTLD) spectrum disorders. Clinically, bvFTD includes progressive decline in social conduct and executive function associated with two major classes of underlying neuropathology: inclusions composed of the microtubule-binding protein, tau (i.e. FTLD-tau), and inclusions of the RNA-binding protein, TDP-43 (i.e. FTLD- TDP). Current drug development efforts are focused on prevention of pathological tau or TDP-43 aggregation in the brain. Although 20% of cases have a pathogenic mutation resulting in FTLD-tau or FTLD-TDP, most cases are sporadic and there is currently no reliable way to detect the underlying molecular etiology in living patients, posing a significant challenge for clinical trials of these emerging therapies. The scientific goal of thi proposal is to subdivide bvFTD into screening phenotypes with biological relevance (i.e. end phenotypes) with the hypothesis that differing patterns of neuron-to-neuron spread of tau and TDP aggregations in bvFTD are associated with unique clinical and genetic features that can be detected ante mortem.
Aim#1 will use a novel approach to quantify differences in regional spread of neuropathology within front temporal networks for comparative study in bvFTD with FTLD-tau vs. FTLD-TDP.
Aim#2 will examine the diagnostic value of risk alleles identified in previous case-control FTLD genome-wide association studies in autopsied sporadic bvFTD, and assess their relationship to QRP map pathology burden.
Aim 3 will integrate clinical and genetic markers in Aims #1 and 2 using advanced statistical techniques in patient classification to identify end phenotypes. Successful completion of these projects will have immediate utility for clinical practice and trial design for disease-modifying therapies in bvFTD. Through work on these specific aims, the structured career development plan will expand the candidate's training to include novel approaches to digital quantitative neuropathology, social cognition, neurogenesis and advanced statistical methods of patient classification under guidance from internationally-recognized leaders in the field. The proposed work will serve as the basis for a future R01 proposal studying prospective multimodal biomarker changes in these end phenotypes.
The behavioral-variant of front temporal dementia (bvFTD) is a common cause of young-onset dementia with no FDA-approved treatment. Emerging disease-modifying therapies aim to prevent the aggregation of pathological proteins specific to neuropath logical subtypes of disease (i.e. tau, TDP-43), but a major obstacle to successful clinical trial development is the clinical, genetic and neuropath logical heterogeneity of the disorder. The overall aim of this study is to identify phenotypic subtypes of bvFTD with similar biological underpinnings to improve clinical bedside diagnostics and maximize statistical power for developing clinical trials in bvFTD.
|Gibbons, Garrett S; Banks, Rachel A; Kim, Bumjin et al. (2018) Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies. J Neuropathol Exp Neurol 77:216-228|
|Shi, Min; Tang, Lu; Toledo, Jon B et al. (2018) Cerebrospinal fluid ?-synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimers Dement 14:1052-1062|
|Lleó, Alberto; Irwin, David J; Illán-Gala, Ignacio et al. (2018) A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurol 75:738-745|
|Irwin, David J; Xie, Sharon X; Coughlin, David et al. (2018) CSF tau and ?-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology 90:e1038-e1046|
|Alcolea, Daniel; Irwin, David J; Illán-Gala, Ignacio et al. (2018) Elevated YKL-40 and low sAPP?:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. J Neurol Neurosurg Psychiatry :|
|Phillips, Jeffrey S; Das, Sandhitsu R; McMillan, Corey T et al. (2018) Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Hum Brain Mapp 39:691-708|
|Irwin, David J; Hurtig, Howard I (2018) The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders. J Alzheimers Dis Parkinsonism 8:|
|Kovacs, Gabor G; Kwong, Linda K; Grossman, Murray et al. (2018) Tauopathy with hippocampal 4-repeat tau immunoreactive spherical inclusions: a report of three cases. Brain Pathol 28:274-283|
|Olm, Christopher A; McMillan, Corey T; Irwin, David J et al. (2018) Longitudinal structural gray matter and white matter MRI changes in presymptomatic progranulin mutation carriers. Neuroimage Clin 19:497-506|
|Ferraro, Pilar M; Jester, Charles; Olm, Christopher A et al. (2018) Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies. Neurobiol Aging 68:85-92|
Showing the most recent 10 out of 55 publications